Q3 results Of course we are in a pandemic and some patients couldn't get their diagnostics but it is hard to believe than revenues will go down significantly. GBT's drugs are repeat business if not close to recurring revenues by nature.
The issue is likely for the launching. Let see. Will be nice to see consolidated results with GBT for at least a month. In this environment I would be happy with lower Adjusted earnings. That said my estimate are maybe a bit too high.